Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483204 | 0.89 | CHEK1 (0.44) | ALOX15CHEK1F2 | |
| SCHEMBL5478092 | 0.88 | CHEK1 (0.46) | HTR2AHTR2CALOX15CHEK1F2 | |
| SCHEMBL5470252 | 0.88 | HTR2A (0.41) | HTR2AHTR2CALOX15CHEK1F2 | |
| SCHEMBL5470777 | 0.84 | CHEK1 (0.44) | CHEK1CD274 | |
| SCHEMBL5469684 | 0.83 | CHEK1 (0.57) | CHEK1 | |
| SCHEMBL14492153 | 0.81 | CHEK1 (0.53) | CHEK1 | |
| SCHEMBL5470173 | 0.80 | CHEK1 (0.44) | CHEK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5477671 | 0.79 | CHEK1 (0.44) | CHEK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5472683 | 0.77 | CHEK1 (0.46) | CHEK1CD274 | |
| SCHEMBL5475543 | 0.76 | CHEK1 (0.40) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | HTR2A 4549/4885HTR2C 3842/4885ALOX15 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.